Comparisons of characteristics between VCT subjects with recent and those with long-term HIV infections who were linked to HIV care
| Characteristic . | All patients,aN = 557 . | Recent infections, N = 264 . | Long-term infections, N = 286 . | P . |
|---|---|---|---|---|
| Male, n (%) | 543 (97.5) | 262 (99.2) | 274 (95.8) | 0.01* |
| Age (years), mean ± SD | 29.5 ± 7.2 | 27.5 ± 5.8 | 31.3 (±7.8) | <0.001* |
| ≤25 years, n (%) | 163 (29.3) | 101 (38.3) | 60 (21.0) | <0.001* |
| Risk, n (%) | 0.10 | |||
| MSM | 527 (94.6) | 255 (96.6) | 267 (93.4) | |
| heterosexual | 26 (4.7) | 7 (2.7) | 18 (6.3) | |
| IDU with needle sharing | 4 (0.7) | 2 (0.8) | 1 (0.4) | |
| Reasons for screening, n (%) | ||||
| having confirmed HIV-infected sexual partners | 102 (18.3) | 34 (12.9) | 67 (23.4) | 0.001* |
| having an IDU partner | 2 (0.4) | 2 (0.8) | 0 (0.0) | 0.23 |
| ever having an STI | 132 (23.7) | 60 (22.7) | 71 (24.8) | 0.62 |
| having transactional sex | 30 (5.4) | 21 (8.0) | 9 (3.2) | 0.01* |
| having a one-night stand | 246 (44.2) | 132 (50.0) | 110 (38.5) | 0.01* |
| having anal sex | 438 (78.6) | 231 (87.5) | 202 (70.6) | <0.001* |
| having oral sex | 432 (77.6) | 225 (85.2) | 201 (70.3) | <0.001* |
| illicit drug use | 147 (26.4) | 75 (28.4) | 70 (24.5) | 0.33 |
| Baseline laboratory results | ||||
| RPR ≥4, n (%) | 70 (12.6) | 27 (10.2) | 42 (14.7) | 0.12 |
| western blot for HIV-1, n (%) | <0.001* | |||
| positive | 510 (91.6) | 222 (84.1) | 283 (99.0) | |
| indeterminate | 37 (6.6) | 35 (13.3) | 0 (0.0) | |
| PVL (log10 copies/mL), mean ± SD | 4.60 ± 0.76 | 4.75 ± 0.82 | 4.47 (±0.66) | <0.001* |
| >5 log10 copies/mL, n (%) | 157 (28.2) | 98 (37.1) | 56 (19.6) | <0.001* |
| CD4 cell count (cells/mm3), mean ± SD | 388.4 ± 209.5 | 436.8 ± 220.7 | 345.8 (±187.5) | <0.001* |
| >500 cells/mm3, n (%) | 138 (24.8) | 83 (31.4) | 52 (18.2) | <0.001* |
| HBsAg positivity, n (%) | 53 (9.5) | 20 (7.6) | 32 (11.2) | 0.19 |
| anti-HCV positivity, n (%) | 18 (3.2) | 5 (1.9) | 11 (3.8) | 0.21 |
| available genotypic resistance results, n (%) | 440 (79.0) | 212 (80.3) | 224 (78.3) | 0.52 |
| Characteristic . | All patients,aN = 557 . | Recent infections, N = 264 . | Long-term infections, N = 286 . | P . |
|---|---|---|---|---|
| Male, n (%) | 543 (97.5) | 262 (99.2) | 274 (95.8) | 0.01* |
| Age (years), mean ± SD | 29.5 ± 7.2 | 27.5 ± 5.8 | 31.3 (±7.8) | <0.001* |
| ≤25 years, n (%) | 163 (29.3) | 101 (38.3) | 60 (21.0) | <0.001* |
| Risk, n (%) | 0.10 | |||
| MSM | 527 (94.6) | 255 (96.6) | 267 (93.4) | |
| heterosexual | 26 (4.7) | 7 (2.7) | 18 (6.3) | |
| IDU with needle sharing | 4 (0.7) | 2 (0.8) | 1 (0.4) | |
| Reasons for screening, n (%) | ||||
| having confirmed HIV-infected sexual partners | 102 (18.3) | 34 (12.9) | 67 (23.4) | 0.001* |
| having an IDU partner | 2 (0.4) | 2 (0.8) | 0 (0.0) | 0.23 |
| ever having an STI | 132 (23.7) | 60 (22.7) | 71 (24.8) | 0.62 |
| having transactional sex | 30 (5.4) | 21 (8.0) | 9 (3.2) | 0.01* |
| having a one-night stand | 246 (44.2) | 132 (50.0) | 110 (38.5) | 0.01* |
| having anal sex | 438 (78.6) | 231 (87.5) | 202 (70.6) | <0.001* |
| having oral sex | 432 (77.6) | 225 (85.2) | 201 (70.3) | <0.001* |
| illicit drug use | 147 (26.4) | 75 (28.4) | 70 (24.5) | 0.33 |
| Baseline laboratory results | ||||
| RPR ≥4, n (%) | 70 (12.6) | 27 (10.2) | 42 (14.7) | 0.12 |
| western blot for HIV-1, n (%) | <0.001* | |||
| positive | 510 (91.6) | 222 (84.1) | 283 (99.0) | |
| indeterminate | 37 (6.6) | 35 (13.3) | 0 (0.0) | |
| PVL (log10 copies/mL), mean ± SD | 4.60 ± 0.76 | 4.75 ± 0.82 | 4.47 (±0.66) | <0.001* |
| >5 log10 copies/mL, n (%) | 157 (28.2) | 98 (37.1) | 56 (19.6) | <0.001* |
| CD4 cell count (cells/mm3), mean ± SD | 388.4 ± 209.5 | 436.8 ± 220.7 | 345.8 (±187.5) | <0.001* |
| >500 cells/mm3, n (%) | 138 (24.8) | 83 (31.4) | 52 (18.2) | <0.001* |
| HBsAg positivity, n (%) | 53 (9.5) | 20 (7.6) | 32 (11.2) | 0.19 |
| anti-HCV positivity, n (%) | 18 (3.2) | 5 (1.9) | 11 (3.8) | 0.21 |
| available genotypic resistance results, n (%) | 440 (79.0) | 212 (80.3) | 224 (78.3) | 0.52 |
HCV, hepatitis C virus; IDU, injecting drug users; RPR, rapid plasma reagin.
*P < 0.05.
aIncluding seven patients with undetermined duration of HIV-1 infection by the BED assay.
Comparisons of characteristics between VCT subjects with recent and those with long-term HIV infections who were linked to HIV care
| Characteristic . | All patients,aN = 557 . | Recent infections, N = 264 . | Long-term infections, N = 286 . | P . |
|---|---|---|---|---|
| Male, n (%) | 543 (97.5) | 262 (99.2) | 274 (95.8) | 0.01* |
| Age (years), mean ± SD | 29.5 ± 7.2 | 27.5 ± 5.8 | 31.3 (±7.8) | <0.001* |
| ≤25 years, n (%) | 163 (29.3) | 101 (38.3) | 60 (21.0) | <0.001* |
| Risk, n (%) | 0.10 | |||
| MSM | 527 (94.6) | 255 (96.6) | 267 (93.4) | |
| heterosexual | 26 (4.7) | 7 (2.7) | 18 (6.3) | |
| IDU with needle sharing | 4 (0.7) | 2 (0.8) | 1 (0.4) | |
| Reasons for screening, n (%) | ||||
| having confirmed HIV-infected sexual partners | 102 (18.3) | 34 (12.9) | 67 (23.4) | 0.001* |
| having an IDU partner | 2 (0.4) | 2 (0.8) | 0 (0.0) | 0.23 |
| ever having an STI | 132 (23.7) | 60 (22.7) | 71 (24.8) | 0.62 |
| having transactional sex | 30 (5.4) | 21 (8.0) | 9 (3.2) | 0.01* |
| having a one-night stand | 246 (44.2) | 132 (50.0) | 110 (38.5) | 0.01* |
| having anal sex | 438 (78.6) | 231 (87.5) | 202 (70.6) | <0.001* |
| having oral sex | 432 (77.6) | 225 (85.2) | 201 (70.3) | <0.001* |
| illicit drug use | 147 (26.4) | 75 (28.4) | 70 (24.5) | 0.33 |
| Baseline laboratory results | ||||
| RPR ≥4, n (%) | 70 (12.6) | 27 (10.2) | 42 (14.7) | 0.12 |
| western blot for HIV-1, n (%) | <0.001* | |||
| positive | 510 (91.6) | 222 (84.1) | 283 (99.0) | |
| indeterminate | 37 (6.6) | 35 (13.3) | 0 (0.0) | |
| PVL (log10 copies/mL), mean ± SD | 4.60 ± 0.76 | 4.75 ± 0.82 | 4.47 (±0.66) | <0.001* |
| >5 log10 copies/mL, n (%) | 157 (28.2) | 98 (37.1) | 56 (19.6) | <0.001* |
| CD4 cell count (cells/mm3), mean ± SD | 388.4 ± 209.5 | 436.8 ± 220.7 | 345.8 (±187.5) | <0.001* |
| >500 cells/mm3, n (%) | 138 (24.8) | 83 (31.4) | 52 (18.2) | <0.001* |
| HBsAg positivity, n (%) | 53 (9.5) | 20 (7.6) | 32 (11.2) | 0.19 |
| anti-HCV positivity, n (%) | 18 (3.2) | 5 (1.9) | 11 (3.8) | 0.21 |
| available genotypic resistance results, n (%) | 440 (79.0) | 212 (80.3) | 224 (78.3) | 0.52 |
| Characteristic . | All patients,aN = 557 . | Recent infections, N = 264 . | Long-term infections, N = 286 . | P . |
|---|---|---|---|---|
| Male, n (%) | 543 (97.5) | 262 (99.2) | 274 (95.8) | 0.01* |
| Age (years), mean ± SD | 29.5 ± 7.2 | 27.5 ± 5.8 | 31.3 (±7.8) | <0.001* |
| ≤25 years, n (%) | 163 (29.3) | 101 (38.3) | 60 (21.0) | <0.001* |
| Risk, n (%) | 0.10 | |||
| MSM | 527 (94.6) | 255 (96.6) | 267 (93.4) | |
| heterosexual | 26 (4.7) | 7 (2.7) | 18 (6.3) | |
| IDU with needle sharing | 4 (0.7) | 2 (0.8) | 1 (0.4) | |
| Reasons for screening, n (%) | ||||
| having confirmed HIV-infected sexual partners | 102 (18.3) | 34 (12.9) | 67 (23.4) | 0.001* |
| having an IDU partner | 2 (0.4) | 2 (0.8) | 0 (0.0) | 0.23 |
| ever having an STI | 132 (23.7) | 60 (22.7) | 71 (24.8) | 0.62 |
| having transactional sex | 30 (5.4) | 21 (8.0) | 9 (3.2) | 0.01* |
| having a one-night stand | 246 (44.2) | 132 (50.0) | 110 (38.5) | 0.01* |
| having anal sex | 438 (78.6) | 231 (87.5) | 202 (70.6) | <0.001* |
| having oral sex | 432 (77.6) | 225 (85.2) | 201 (70.3) | <0.001* |
| illicit drug use | 147 (26.4) | 75 (28.4) | 70 (24.5) | 0.33 |
| Baseline laboratory results | ||||
| RPR ≥4, n (%) | 70 (12.6) | 27 (10.2) | 42 (14.7) | 0.12 |
| western blot for HIV-1, n (%) | <0.001* | |||
| positive | 510 (91.6) | 222 (84.1) | 283 (99.0) | |
| indeterminate | 37 (6.6) | 35 (13.3) | 0 (0.0) | |
| PVL (log10 copies/mL), mean ± SD | 4.60 ± 0.76 | 4.75 ± 0.82 | 4.47 (±0.66) | <0.001* |
| >5 log10 copies/mL, n (%) | 157 (28.2) | 98 (37.1) | 56 (19.6) | <0.001* |
| CD4 cell count (cells/mm3), mean ± SD | 388.4 ± 209.5 | 436.8 ± 220.7 | 345.8 (±187.5) | <0.001* |
| >500 cells/mm3, n (%) | 138 (24.8) | 83 (31.4) | 52 (18.2) | <0.001* |
| HBsAg positivity, n (%) | 53 (9.5) | 20 (7.6) | 32 (11.2) | 0.19 |
| anti-HCV positivity, n (%) | 18 (3.2) | 5 (1.9) | 11 (3.8) | 0.21 |
| available genotypic resistance results, n (%) | 440 (79.0) | 212 (80.3) | 224 (78.3) | 0.52 |
HCV, hepatitis C virus; IDU, injecting drug users; RPR, rapid plasma reagin.
*P < 0.05.
aIncluding seven patients with undetermined duration of HIV-1 infection by the BED assay.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
